VivoSeq
Ophthalmology

Rhegmatogenous Retinal Detachment

9

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Rhegmatogenous Retinal Detachment is an early-stage landscape with 9 programs across 6 companies. The most active players are ONL Therapeutics, Daewoong Pharmaceutical Co. LTD., Merck & Co.. 1 therapy is approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

ONL Therapeutics

1 program

Phase 1Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.

1 program

Phase 1Merck & Co. logo

Merck & Co.

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3AbbVie logo

AbbVie

1 program

ApprovedGSK logo

GSK

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed5 · 45%
Recruiting3 · 27%
Unknown status2 · 18%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy
Recruiting·UUnity Health Toronto·Phase 2·NCT05523869·50 enrolled
Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery
Recruiting·HHopital Foch·Phase 3·NCT06294847·120 enrolled
Dropless Pars Plana Vitrectomy Study
Recruiting·MMassachusetts Eye and Ear Infirmary·Approved·NCT05331664·168 enrolled
Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment
Completed·—·N/A·NCT06347302·137 enrolled
Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment
Completed·TTianjin Medical University Eye Hospital·N/A·NCT03542162·37 enrolled
Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy
Completed·IIndonesia University·Phase 4·NCT07162818·61 enrolled
A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Completed·OONL Therapeutics·Phase 1·NCT03780972·14 enrolled
Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment
Completed·—·Phase 1·NCT02841306·26 enrolled
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
Terminated·Merck & Co. logoMerck & Co.·Phase 2·NCT00083967·23 enrolled
Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment
Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT02185469·30 enrolled
Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
Unknown status·SShahid Beheshti University of Medical Sciences·Phase 3·NCT00370201

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)